This study aimed to clarify its mechanism via a multi-omics strategy.<h4>Methods</h4>A multi-omics integration approach was adopted, which combined single-cell RNA sequencing, in vitro experiments, the construction of a Glutathione S-transferase P1 (GSTP1)-based prognostic model, and analyses of immune infiltration and drug sensitivity to evaluate its clinical value.<h4>Results</h4>C2 CENPF+ tumor cells were specifically expressed in recurrent gliomas and associated with the bioA pathway. The gene discussed is CENPF; the disease is glioma.